SCHEMBL11215850

SCHEMBL11215850

C=CCC(C)(O)CCC=C(C)C

nearest known ligand 0.61

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 5/20 0.61
HIF1A Q16665 4/20 0.39
EPAS1 Q99814 4/20 0.39
TSHR P16473 1/20 0.39
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.35
CYP3A4 P08684 2/20 0.35
MAPK1 P28482 1/20 0.35
CHRNA7 P36544 1/20 0.35
STAT3 P40763 1/20 0.35
GGPS1 O95749 6/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25252922 0.81 ALOX15 (0.59) ALOX15HIF1AEPAS1TSHRKMT2A
SCHEMBL9575207 0.80 ALOX15 (0.57) ALOX15HIF1AEPAS1TSHRKMT2A
SCHEMBL30366157 0.78 ALOX15 (0.50) ALOX15TSHRKMT2AMEN1CYP3A4
SCHEMBL9390107 0.78 MAPT (0.38) ALOX15TSHRKMT2AMEN1CYP3A4
SCHEMBL214881 0.77 ALOX15 (0.54) ALOX15HIF1AEPAS1TSHRKMT2A
SCHEMBL18643950 0.77 ALOX15 (0.54) ALOX15HIF1AEPAS1TSHRKMT2A
SCHEMBL5907126 0.77 ALOX15 (0.54) ALOX15HIF1AEPAS1TSHRKMT2A
SCHEMBL17106157 0.76 ALOX15 (0.48) ALOX15HIF1AEPAS1TSHRCYP3A4
SCHEMBL17106152 0.76 ALOX15 (0.48) ALOX15HIF1AEPAS1TSHRCYP3A4
SCHEMBL17106247 0.76 ALOX15 (0.48) ALOX15HIF1AEPAS1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12194020-B2 Reversing baldness through cannabinoid receptor activation POSTREL RICHARD (US) 2025-01-14 US claimed
US-20220249434-A1 Reversal of Baldness in Men and Women through Cannabinoid Receptor Activation POSTREL RICHARD (US) 2022-08-11 US claimed
US-11331300-B2 Reversing baldness through follicle regeneration POSTREL RICHARD (US) 2022-05-17 US claimed
US-20200078333-A1 Healthier Aging in Domesticated Animals POSTREL RICHARD (US) 2020-03-12 US claimed
US-20190030044-A1 HUMAN LIFE EXTENSION THERAPY THROUGH MOLECULAR, CELLULAR AND SUBCELLULAR MANAGEMENT OF BIOCHEMICAL REQUIREMENTS OF MITOCHONDRIA AND OF OTHER ORGANELLE PROCESSES ASSOCIATED WITH THE ADVENT OF DISEASE AND/OR AGING POSTREL RICHARD (US) 2019-01-31 US claimed
US-20190029993-A1 QUALITY OF LIFE EXTENSION THERAPIES RELATING TO AGING, FOOD ALLERGIES, PAIN AND REDUCED VIGOR BY MANAGING MOLECULAR, CELLULAR AND SUBCELLULAR BIOCHEMICAL REQUIREMENTS OF MITOCHONDRIA AND OTHER ORGANELLE PROCESSES REVIGORON LLC 2019-01-31 US claimed
WO-2018118197-A1 HEALTHIER AGING IN DOMESTICATED ANIMALS POSTREL RICHARD (US) 2018-06-28 WO claimed
JP-57011978-A None JP disclosed
US-20250205175-A1 Anti-Aging Composition with mTOR inhibitor for Humans and Other Mammals POSTREL RICHARD (US) 2025-06-26 US disclosed
US-20250152562-A1 Compositions to Enhance and Extend Quality of Life POSTREL RICHARD (US) 2025-05-15 US disclosed
US-12280019-B2 Anti-aging therapy for humans and other mammals POSTREL RICHARD (US) 2025-04-22 US disclosed
US-12220407-B2 Life extension for humans and other mammals POSTREL RICHARD (US) 2025-02-11 US disclosed
US-12201589-B2 Anti-aging therapy for canines and other domesticated animals POSTREL RICHARD (US) 2025-01-21 US disclosed
US-20190054135-A1 PLANT OR MICROORGANISM-DERIVED CAROTENOID-OXYGEN COPOLYMER COMPOSITIONS, METHODS OF IDENTIFYING, QUANTIFYING AND PRODUCING SAME AND USES THEREOF AVIVAGEN INC. (CA) 2019-02-21 US disclosed
US-20190030044-A1 HUMAN LIFE EXTENSION THERAPY THROUGH MOLECULAR, CELLULAR AND SUBCELLULAR MANAGEMENT OF BIOCHEMICAL REQUIREMENTS OF MITOCHONDRIA AND OF OTHER ORGANELLE PROCESSES ASSOCIATED WITH THE ADVENT OF DISEASE AND/OR AGING POSTREL RICHARD (US) 2019-01-31 US disclosed
US-20190029993-A1 QUALITY OF LIFE EXTENSION THERAPIES RELATING TO AGING, FOOD ALLERGIES, PAIN AND REDUCED VIGOR BY MANAGING MOLECULAR, CELLULAR AND SUBCELLULAR BIOCHEMICAL REQUIREMENTS OF MITOCHONDRIA AND OTHER ORGANELLE PROCESSES REVIGORON LLC 2019-01-31 US disclosed
EP-3420004-A1 PLANT OR MICROORGANISM-DERIVED CAROTENOID-OXYGEN COPOLYMER COMPOSITIONS, METHODS OF IDENTIFYING, QUANTIFYING AND PRODUCING SAME AND USES THEREOF Avivagen Inc. (CA) 2019-01-02 EP disclosed
WO-2018118197-A1 HEALTHIER AGING IN DOMESTICATED ANIMALS POSTREL RICHARD (US) 2018-06-28 WO disclosed
WO-2017143460-A1 PLANT OR MICROORGANISM-DERIVED CAROTENOID-OXYGEN COPOLYMER COMPOSITIONS, METHODS OF IDENTIFYING, QUANTIFYING AND PRODUCING SAME AND USES THEREOF AVIVAGEN INC. (CA) 2017-08-31 WO disclosed
JP-S5711978-A 2,6,6-TRIMETHYL-2-(2-PROPYNYL OR ALLYL)-TETRAHYDROPYRAN, ITS PREPARATION AND UTILIZATION T HASEGAWA CO LTD 1982-01-21 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190054135-A1 PLANT OR MICROORGANISM-DERIVED CAROTENOID-OXYGEN COPOLYMER COMPOSITIONS, METHODS OF IDENTIFYING, QUANTIFYING AND PRODUCING SAME AND USES THEREOF PPOX, LPO, CBR3 ALOX15 37/4885HIF1A 628/4885EPAS1 1666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.